The Medical Letter - 2026
August 3, 2026 (Issue 1760)
Bemotrizinol — A New Sunscreen
Bemotrizinol (bis-ethylhexyloxyphenol methoxyphenol triazine), a broad-spectrum, organic ultraviolet (UV) filter that has been available in Europe since 2000, is the first new active ingredient with broad availability to be added to the FDA's OTC sunscreen monograph in more than 25 years, and the first organic UV filter to be generally recognized as safe and effective (GRASE). Data with other organic UV filters are insufficient for a GRASE designation.
Icotrokinra (Icotyde) for Psoriasis
The FDA has approved the oral interleukin (IL)-23 receptor antagonist icotrokinra ( Icotyde – Janssen) for treatment of moderate to severe plaque psoriasis in patients ≥12 years old who are candidates for systemic treatment or phototherapy. Icotrokinra is the first oral targeted interleukin blocker to become available in the US.
Mitapivat (Aqvesme) for Thalassemia
Mitapivat ( Aqvesme – Agios), an oral pyruvate kinase activator, has been approved by the FDA for treatment of anemia in adults with alpha or beta thalassemia. It is the first product to be approved in the US for treatment of alpha thalassemia and the first oral option for beta thalassemia. Mitapivat was approved in 2022 as Pyrukind for treatment of hemolytic anemia in adults with pyruvate kinase deficiency.
Sibeprenlimab (Voyxact) for Primary Immunoglobulin A Nephropathy
Sibeprenlimab ( Voyxact – Otsuka), a subcutaneously injected cytokine A proliferation-inducing ligand (APRIL) blocker, has been granted accelerated approval by the FDA to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN; also called Berger's disease) who are at risk for disease progression. Sibeprenlimab is the first APRIL blocker to be approved in the US. Atacicept (Trutakna) , a B-lymphocyte stimulator and APRIL blocker, was recently granted accelerated FDA approval for the same indication; it will be reviewed in a future issue.
Inqovi for Acute Myeloid Leukemia (online only)
The FDA has approved Inqovi (Taiho Oncology), a fixed-dose combination of the nucleoside metabolic inhibitor decitabine and the cytidine deaminase inhibitor cedazuridine, for use in combination with venetoclax ( Venclexta , and generics) for oral treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are ≥75 years old or who have comorbidities that prevent use of intensive induction chemotherapy. The combination was approved in 2020 for treatment of myelodysplastic syndromes (MDS). IV decitabine or azacitidine plus oral venetoclax has been used for treatment of newly diagnosed AML for years.
July 20, 2026 (Issue 1759)
Ensitrelvir (Xocova) for Post-Exposure Prophylaxis of COVID-19 Free
The FDA has approved ensitrelvir ( Xocova – Shionogi), a SARS-CoV-2 main protease inhibitor, for postexposure prophylaxis of COVID-19 in patients ≥12 years old who had contact with an infected individual. Ensitrelvir is the first oral antiviral drug to be approved in the US for this indication. The parenteral monoclonal antibody combinations bamlanivimab and etesevimab and casirivimab and imdevimab (REGEN-COV) are no longer authorized for postexposure prophylaxis of COVID-19 in the US.
Omidenepag Isopropyl (Omlonti) for Glaucoma
The FDA has approved Omlonti (Ocuvex), a 0.002% ophthalmic solution of the prostaglandin EP 2 receptor agonist omidenepag isopropyl, for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Omidenepag is the first selective prostaglandin EP 2 receptor agonist to be approved in the US. It has been available in Japan since 2018.
In Brief: New Warning for OTC Orlistat (Alli) Free
The FDA now requires a warning about a risk of acute kidney injury in the product label for the 60-mg capsules of the pancreatic and gastric lipase inhibitor orlistat, which are available over the counter as Alli for weight loss.1 The label for the 120-mg capsules, which are available by prescription as Xenical , already includes a warning about a risk of oxalate nephrolithiasis and oxalate nephropathy (orlistat increases oxalate absorption).
OTC Differin Epiduo Gel for Acne Free
Differin Epiduo gel (Galderma), a fixed-dose combination of the synthetic retinoid adapalene 0.1% and the oxidizing agent benzoyl peroxide 2.5%, is now available over the counter (OTC) for topical treatment of acne in patients ≥12 years old. It will remain available by prescription for use in patients 9-11 years old. A gel containing adapalene 0.3% and benzoyl peroxide 2.5% ( Epiduo Forte , and generics) is available by prescription for use in patients ≥12 years old.
Drugs for Hypertriglyceridemia
Adults with persistent fasting triglyceride levels ≥150 mg/dL are considered to have hypertriglyceridemia; when levels are ≥500 mg/dL, it is considered severe. Hypertriglyceridemia is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD); severe hypertriglyceridemia increases the risk of acute pancreatitis.
Sonrotoclax (Beqalzi) for Mantle Cell Lymphoma
The FDA has granted accelerated approval to the B-cell lymphoma 2 (BCL-2) inhibitor sonrotoclax ( Beqalzi – BeOne Medicines) for treatment of relapsed or refractory mantle cell lymphoma (MCL) in adults who received ≥2 prior lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor (e.g., pirtobrutinib [Jaypirca] ), acalabrutinib [Calquence] , or zanubrutinib [Brukinsa] ). Sonrotoclax is the first BCL-2 inhibitor to be approved in the US for this indication. The BCL-2 inhibitor venetoclax (Venclexta) has been used off label for third-line treatment of MCL.
Vepdegestrant (Veppanu) for Advanced Breast Cancer
Vepdegestrant ( Veppanu – Rigel), an oral heterobifunctional protein degrader, has been approved by the FDA for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer in adults who had disease progression following ≥1 prior line of endocrine therapy. It is the first proteolysis targeting chimera (PROTAC), a type of heterobifunctional protein degrader, to be approved in the US. The oral selective estrogen receptor degraders (SERDs) elacestrant (Orserdu) and imlunestrant (Inluriyo) were approved earlier for the same…
July 6, 2026 (Issue 1758)
Baxdrostat (Baxfendy) — An Aldosterone Synthase Inhibitor for Hypertension
The FDA has approved baxdrostat ( Baxfendy – AstraZeneca), an oral aldosterone synthase inhibitor, for add-on treatment of hypertension in adults whose blood pressure is not adequately controlled on other drugs. Baxdrostat is the first aldosterone synthase inhibitor to become available in the US.
Fosfomycin (Contepo) for Complicated Urinary Tract Infections
The FDA has approved an IV formulation of the epoxide antibacterial drug fosfomycin ( Contepo – Meitheal) for treatment of adults with complicated urinary tract infections (cUTIs) caused by susceptible isolates of Escherichia coli or Klebsiella pneumoniae . Oral fosfomycin has been available in the US for years for treatment of uncomplicated urinary tract infections. IV fosfomycin has been available in other countries for decades.
Breztri Aerosphere for Asthma
Breztri Aerosphere (AstraZeneca), a three-drug inhaler containing the inhaled corticosteroid (ICS) budesonide, the long-acting antimuscarinic agent (LAMA) glycopyrrolate, and the long-acting beta 2 -agonist (LABA) formoterol fumarate, has been approved by the FDA for maintenance treatment of asthma in patients ≥12 years old. It was approved in 2020 for treatment of chronic obstructive pulmonary disease (COPD). Breztri Aerosphere is the second ICS/LAMA/LABA combination to become available for treatment of asthma. Trelegy Ellipta , which contains the ICS fluticasone, the LAMA umeclidinium, and the LABA vilanterol, is FDA-approved for…
Inebilizumab (Uplizna) for Myasthenia Gravis
The FDA has approved the CD19-directed cytolytic antibody inebilizumab ( Uplizna – Amgen) for IV treatment of generalized myasthenia gravis (gMG) in adults with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. The neonatal Fc receptor (FcRn) blockers rozanolixizumab (Rystiggo) , nipocalimab (Imaavy) , and efgartigimod alfa (Vyvgart; Vyvgart Hytrulo) are also approved for such use (see Table 1).
June 22, 2026 (Issue 1757)
Tradipitant (Nereus) for Motion Sickness
The FDA has approved the oral substance P/neurokinin-1 (NK-1) receptor antagonist tradipitant ( Nereus – Vanda) for prevention of vomiting induced by motion in adults. Tradipitant is the first drug to be approved for motion sickness in more than 40 years. Other oral substance P/NK-1 receptor antagonists (i.e., aprepitant, rolapitant, and netupitant) have been available for years for prevention of chemotherapy-induced nausea and vomiting.
Dextromethorphan/Bupropion (Auvelity) for Agitation in Alzheimer’s Dementia
Auvelity (Axsome), an extended-release fixed-dose combination of dextromethorphan and bupropion that was approved by the FDA for treatment of major depressive disorder in 2022, has now been approved for treatment of agitation associated with dementia due to Alzheimer's disease (AD). It is the second product to be approved in the US for this indication; the oral second-generation antipsychotic drug brexpiprazole (Rexulti) was approved in 2023.
In Brief: An Expanded Indication for Teplizumab (Tzield) Free
The CD3-directed monoclonal antibody teplizumab ( Tzield – Provention Bio), which was previously approved by the FDA to delay the onset of stage 3 type 1 diabetes in patients ≥8 years old with stage 2 type 1 diabetes, has now been approved for such use in children 1-7 years old.
In Brief: Widaplik — Another Three-Drug Combination for Hypertension Free
The FDA has approved Widaplik (Azurity), a fixed-dose combination of the angiotensin receptor blocker (ARB) telmisartan, the dihydropyridine calcium channel blocker amlodipine, and the thiazide-like diuretic indapamide, for treatment of hypertension in adults. Telmisartan, amlodipine, and indapamide are also available alone and in various combinations for treatment of hypertension. Two three-drug combinations containing an ARB, amlodipine, and the thiazide diuretic hydrochlorothiazide ( Exforge HCT and Tribenzor ) have been available for years (see Table 1).
In Brief: Dupilumab (Dupixent) for Allergic Fungal Rhinosinusitis Free
Dupilumab ( Dupixent – Sanofi/Regeneron), a subcutaneously injected interleukin (IL)-4 receptor alpha antagonist that is FDA-approved for several indications, including treatment of chronic rhinosinusitis with nasal polyps, has now been approved for treatment of allergic fungal rhinosinusitis (AFRS) in patients ≥6 years old who previously had sinonasal surgery. It is the first drug to be approved in the US for this indication.
In Brief: Apixaban vs Rivaroxaban for Acute VTE Free
The direct oral anticoagulants (DOACs) apixaban (Eliquis) and rivaroxaban ( Xarelto , and generics) are frequently used for treatment of acute venous thromboembolism (VTE) and are usually continued for at least 3 months. The other DOACs (edoxaban [Savaysa] and dabigatran [ Pradaxa , and generics]) are alternatives for long-term treatment, but they require prior treatment with low-molecular-weight heparin for ≥5 days. Until recently, no large randomized trial directly comparing the safety of apixaban and rivaroxaban for treatment of VTE was available.
Comparison Chart: Drugs for Motion Sickness (online only) Free
View the Comparison Chart: Drugs for Motion Sickness
June 8, 2026 (Issue 1756)
Drugs for Hypercholesterolemia
Recently published multisociety guidelines for the management of dyslipidemia emphasize early identification and treatment of dyslipidemia to reduce the lifetime risk of atherosclerotic cardiovascular disease (ASCVD) and death.
Comparison Chart: Statins (online only)
View the Comparison Chart: Statins
Comparison Chart: Some Non-Statin Lipid-Lowering Drugs (online only)
View the Comparison Chart: Some Non-Statin Lipid-Lowering Drugs
May 25, 2026 (Issue 1755)
Orforglipron (Foundayo) – A Second Oral GLP-1 Receptor Agonist for Weight Loss
The FDA has approved orforglipron ( Foundayo – Lilly), an oral small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight and at least one weight-related comorbidity. Orforglipron is the second oral GLP-1 receptor agonist to be approved in the US for this indication; an oral formulation of the peptide semaglutide (Wegovy) was approved in 2025.
Yuvezzi — A Carbachol/Brimonidine Solution for Presbyopia
The FDA has approved Yuvezzi (Tenpoint), an ophthalmic solution containing the cholinergic agonist carbachol 2.75% and the alpha-adrenergic receptor agonist brimonidine 0.1%, for treatment of presbyopia. Carbachol and brimonidine have been available in single-ingredient ophthalmic solutions for other indications for years.
Aficamten (Myqorzo) for Obstructive Hypertrophic Cardiomyopathy
Aficamten ( Myqorzo – Cytokinetics), an oral cardiac myosin inhibitor, has been approved by the FDA to improve functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). It is the second cardiac myosin inhibitor to be approved in the US for this indication; mavacamten (Camzyos) was approved in 2022.
In Brief: An Expanded Indication for Enhertu Free
Fam-trastuzumab deruxtecan ( Enhertu – Daiichi Sankyo/AstraZeneca) has now been approved by the FDA for use in combination with pertuzumab (Perjeta) for first-line treatment of HER2-positive unresectable or metastatic breast cancer. The drug was approved earlier for use as monotherapy in adults with previously treated HER2-positive unresectable or metastatic breast cancer.
May 11, 2026 (Issue 1754)
Lerodalcibep (Lerochol) for Hypercholesterolemia
The FDA has approved lerodalcibep ( Lerochol – Lib Therapeutics), a subcutaneously injected proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Lerodalcibep is the fourth subcutaneously injected PCSK9-directed therapy to be approved in the US; the monoclonal antibodies alirocumab (Praluent) and evolocumab (Repatha) and the small interfering RNA inclisiran (Leqvio) were approved earlier (see Table 3)
Leucovorin for Cerebral Folate Deficiency
The FDA has approved use of oral leucovorin calcium (folinic acid) for treatment of cerebral folate transport deficiency in patients who have a confirmed variant in the folate receptor 1 gene (FOLR1-CFTD). It is the first drug to be approved for this extremely rare disorder.
In Brief: Wegovy HD – High-Dose Injectable Semaglutide for Weight Loss Free
The FDA has approved Wegovy HD , a 7.2-mg dose of the injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, for use in adults who have tolerated the 2.4-mg dose for at least 4 weeks and require additional weight reduction.
In Brief: RSV Vaccine (Arexvy) for Ages 18-49 Free
The FDA has expanded the licensed use of the recombinant respiratory syncytial virus (RSV) vaccine Arexvy (GSK) to include adults 18-49 years old. Arexvy and the two other available RSV vaccines, Abrysvo and mResvia , are now all licensed for prevention of RSV lower respiratory tract disease in persons ≥60 years old and in those 18-59 years old who are at increased risk of lower respiratory tract disease caused by RSV. Abrysvo is also licensed for use in pregnant women at 32-36 weeks' gestation to prevent RSV-associated lower respiratory tract disease in their infants from birth to 6 months.
In Brief: Vybrique — Sildenafil Oral Film for Erectile Dysfunction Free
The FDA has approved Vybrique (IBSA), an oral film formulation of the phosphodiesterase type 5 (PDE5) inhibitor sildenafil, for treatment of erectile dysfunction (ED). Sildenafil oral tablets ( Viagra , and generics) have been available since 1998. The manufacturer is promoting the new product as a "discreet, on-the-go" option that can be taken without water.
Relacorilant (Lifyorli) for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (online only)
Relacorilant ( Lifyorli – Corcept Therapeutics), an oral first-in-class glucocorticoid receptor antagonist, has been approved by the FDA for use in combination with nab-paclitaxel ( Abraxane , and generics) for treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who received 1-3 prior lines of systemic therapy, one of which included bevacizumab ( Avastin , and others).
Nipocalimab (Imaavy) for Myasthenia Gravis (online only)
The FDA has approved the neonatal Fc receptor (FcRn) blocker nipocalimab ( Imaavy – Janssen) for IV treatment of generalized myasthenia gravis (gMG) in patients ≥12 years old with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. The FcRn blocker rozanolixizumab (Rystiggo) was approved earlier for the same indication.
April 27, 2026 (Issue 1753)
Drugs for Sexually Transmitted Infections
This review includes recommendations for the treatment of common sexually transmitted infections (STIs) other than HIV and viral hepatitis in nonpregnant adolescents and adults. Some of the indications and dosages included here have not been approved by the FDA.
In Brief: New Warnings for Carbidopa/Levodopa Products Free
The FDA has required that the labels of all carbidopa/levodopa-containing products (Crexont, Dhivy, Duopa, Rytary, Sinemet, Sinemet CR, Stalevo, Vyalev) include a warning about the risk of vitamin B6 (pyridoxine) deficiency and vitamin B6 deficiency-related seizures associated with their use. The combination of carbidopa/levodopa is the most effective treatment for the motor symptoms of Parkinson's disease and recent evidence favors its early use.
April 13, 2026 (Issue 1752)
Pivmecillinam (Pivya) for Uncomplicated UTI
The FDA has approved pivmecillinam ( Pivya – Utility Therapeutics), an oral penicillin-class antibacterial drug, for treatment of uncomplicated urinary tract infections (uUTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis , or Staphylococcus saprophyticus in adult females. Pivmecillinam was approved by the FDA in 2024 but only recently became available in the US. It has been used in Europe for over 40 years.
Etripamil Nasal Spray (Cardamyst) for Paroxysmal Supraventricular Tachycardia
The FDA has approved Cardamyst (Milestone), a nasal spray formulation of the nondihydropyridine calcium channel blocker etripamil, for conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Cardamyst is the first product containing etripamil to be approved in the US. It is being marketed as the only FDA-approved, self-administered, rapid-acting treatment option for acute episodes of PSVT.
Plozasiran (Redemplo) for Familial Chylomicronemia Syndrome
Plozasiran ( Redemplo – Arrowhead), an apolipoprotein C-III (apoC-III)-directed small interfering ribonucleic acid (siRNA), has been approved by the FDA to reduce triglyceride levels in adults with familial chylomicronemia syndrome (FCS). It is the second drug to be approved in the US for this indication; the apoC-III-directed antisense oligonucleotide olezarsen (Tryngolza) was approved in 2024.
In Brief: A Bumetanide Nasal Spray (Enbumyst) for Edema Free
Enbumyst (Corstasis), a nasal spray formulation of the loop diuretic bumetanide, has been approved by the FDA for (short-term) treatment of edema associated with congestive heart failure, renal disease (including nephrotic syndrome), or hepatic disease in adults. It is the first diuretic nasal spray formulation to become available in the US. Bumetanide has been available for years in oral and IV formulations.
In Brief: Ranitidine Returns Free
The FDA has approved a new tablet formulation of the H2-receptor antagonist (H2RA) ranitidine from one manufacturer (VKT Pharma/Rising Pharma). It is only available by prescription. In 2020, the FDA requested that all formulations of ranitidine be withdrawn from the market because unacceptable levels of the nitrosamine compound N -nitrosodimethylamine (NDMA), a potentially carcinogenic contaminant, had been detected in ranitidine samples.
In Brief: Rybelsus R2 Rebranded as Ozempic Free
Oral semaglutide 1.5-, 4-, and 9-mg tablets, which were previously approved by the FDA (but never marketed) as the R2 formulation of Rybelsus , have now been approved as Ozempic (see Table 1). Both the original R1 formulation of Rybelsus (3-, 7-, and 14-mg tablets) and the renamed Ozempic tablets are FDA-approved for treatment of type 2 diabetes and to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who are at risk for these events. The R1 (Rybelsus) and R2 (Ozempic) formulations are not interchangeable on a mg-per-mg basis; Ozempic tablets contain inactive ingredients that enhance drug absorption…
In Brief: Optune Pax — A Portable Device for Pancreatic Cancer (online only) Free
Optune Pax (Novocure), a portable device that delivers low-intensity alternating electrical fields to the abdomen, has been approved by the FDA for use with gemcitabine and nab-paclitaxel (GnP) for treatment of locally advanced pancreatic cancer in adults. It is the first device to be approved in the US for treatment of pancreatic cancer. Similar devices are available for treatment of certain lung cancers (Optune Lua) and glioblastoma (Optune Gio) .
March 30, 2026 (Issue 1751)
Drugs for Dementia
Alzheimer's disease (AD) is the most common cause of dementia, but cognitive decline also occurs in other neurological conditions, such as Parkinson's disease, Lewy body dementia, vascular dementia, and frontotemporal dementia.
In Brief: Aflibercept (Eylea HD) for Macular Edema Following Retinal Vein Occlusion Free
Eylea HD (Regeneron), which contains 8 mg of the vascular endothelial growth factor (VEGF) inhibitor aflibercept, has now been approved by the FDA for intravitreal treatment of macular edema following retinal vein occlusion (RVO). A 2-mg dose of aflibercept (Eylea) was approved previously for this indication. Eylea and Eylea HD are also approved for treatment of neovascular (wet) age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.
Comparison Table: Drugs for Alzheimer's Disease Dementia (online only)
View the Comparison Table: Drugs for Alzheimer's Disease Dementia
Comparison Table: Amyloid Beta-Directed Antibodies for Alzheimer's Disease (online only)
View the Comparison Table: Amyloid Beta-Directed Antibodies for Alzheimer's Disease
March 16, 2026 (Issue 1750)
Two New Drugs for Gonorrhea
The FDA has approved two antibiotics, gepotidacin ( Blujepa — GSK) and zoliflodacin ( Nuzolvence — Entasis), for oral treatment of uncomplicated urogenital gonorrhea in patients ≥12 years old. Gepotidacin is approved for use in persons weighing ≥45 kg who have limited or no alternative treatment options; it was approved in 2025 for treatment of uncomplicated urinary tract infection in females. Zoliflodacin is approved for use in persons weighing ≥35 kg. Neither drug is indicated for treatment of rectal or pharyngeal gonorrhea.
Depemokimab (Exdensur) for Severe Eosinophilic Asthma
The FDA has approved depemokimab ( Exdensur – GSK), a long-acting interleukin-5 (IL-5) antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients ≥12 years old. Depemokimab is the fourth IL-5-directed treatment to be approved in the US for this indication; the IL-5 antagonists mepolizumab (Nucala) and reslizumab (Cinqair) and the IL-5 receptor alpha antagonist benralizumab (Fasenra) were approved earlier.
Obinutuzumab (Gazyva) for Lupus Nephritis
Obinutuzumab ( Gazyva – Genentech), a CD20-directed monoclonal antibody, has been approved by the FDA for treatment of adults with active lupus nephritis who are receiving standard treatment. It was previously approved for treatment of chronic lymphocytic leukemia and follicular lymphoma. Obinutuzumab is the third drug to be approved in the US for treatment of lupus nephritis; the oral calcineurin inhibitor voclosporin (Lupkynis) and the parenteral B-lymphocyte stimulator (BlyS)-specific inhibitor belimumab (Benlysta) were approved earlier.
In Brief: A Second Subcutaneous Furosemide Infusor (Lasix ONYU) for Heart Failure Free
The FDA has approved Lasix ONYU (SQ Innovation), a subcutaneous formulation of the loop diuretic furosemide administered via a wearable pump (onbody infusor), for treatment of edema in adults with chronic heart failure (HF). A similar product, Furoscix , is approved for treatment of edema in chronic HF or chronic kidney disease. Furosemide has been available for years in oral and IV formulations for such use.
Ziftomenib (Komzifti) for Acute Myeloid Leukemia (online only)
Ziftomenib ( Komzifti – Kura), an oral menin inhibitor, has been approved by the FDA for treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options. It is the second oral menin inhibitor to be approved in the US for this indication; revumenib (Revuforj) was approved in October 2025 for use in patients ≥1 year old.
Correction Free
In our article titled A Renal Indication for Semaglutide (Ozempic) (Med Lett Drugs Ther 2025; 67:38), the MACE endpoint defined in Table 2, footnote 3 was incorrectly stated as a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or all-cause mortality. All-cause mortality should not have been included in the composite endpoint.
March 2, 2026 (Issue 1749)
Drugs for Atopic Dermatitis
Atopic dermatitis (AD), also known as eczema, is frequently associated with other atopic disorders such as allergic rhinitis, asthma, and food allergy. It commonly presents in infancy and early childhood and has a relapsing course, often improving by adolescence, but sometimes persisting into or first appearing in adulthood or even old age. Guidelines for the treatment of AD have recently been updated.
In Brief: Extended Duration of Use for Nexplanon Free
Nexplanon , a single-rod contraceptive implant containing the progestin etonogestrel, has now been approved for prevention of pregnancy for up to 5 years. It was previously approved for up to 3 years of use.
Addendum: Urinary Incontinence with Second-Generation Antipsychotic Drugs Free
Our recent article entitled Lumateperone (Caplyta) for Adjunctive Treatment of Depression should have included urinary incontinence among the adverse effects associated with use of second-generation antipsychotic drugs. Urinary incontinence has been reported with both first- and second-generation antipsychotics. Possible causes include the anti-alpha-adrenergic, antidopaminergic, and anticholinergic effects of these drugs, as well as sedation. In an observational study in 200 women 20-40 years old, urinary incontinence was reported by 29% of those taking antipsychotic drugs and by 13% of age-matched controls.
Comparison Chart: Topical Nonsteroidal Drugs for Atopic Dermatitis (online only) Free
View the Comparison Chart: Topical Nonsteroidal Drugs for Atopic Dermatitis
Comparison Chart: Interleukin (IL) Antagonists and Oral JAK Inhibitors for Moderate to Severe Atopic Dermatitis (online only) Free
View the Comparison Chart: Interleukin (IL) Antagonists and Oral JAK Inhibitors for Moderate to Severe Atopic Dermatitis
February 16, 2026 (Issue 1748)
Aztreonam/Avibactam (Emblaveo) for Complicated Intra-Abdominal Infections
The FDA has approved Emblaveo (Abbvie) , an intravenously administered fixed-dose combination of the monobactam antibacterial drug aztreonam and the beta-lactamase inhibitor avibactam, for use with metronidazole to treat complicated intra-abdominal infections (cIAIs) in adults.
A Treprostinil Inhaler (Yutrepia) for Pulmonary Hypertension
Yutrepia (Liquidia), a dry powder inhaler formulation of the prostacyclin analog treprostinil, has been approved by the FDA to improve exercise ability in adults with pulmonary arterial hypertension (PAH; WHO Group 1) or pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3). Tyvaso DPI , another treprostinil dry powder inhaler, was approved earlier for the same indication.
Sebetralstat (Ekterly) for Treatment of Hereditary Angioedema Attacks
Sebetralstat ( Ekterly – Kalvista), an oral plasma kallikrein inhibitor, has been approved by the FDA for treatment of acute hereditary angioedema (HAE) attacks in patients ≥12 years old. It is the first oral drug to be approved in the US for this indication. The intravenous C1 esterase inhibitors (C1INHs) Berinert and Ruconest , the subcutaneous plasma kallikrein inhibitor ecallantide (Kalbitor) , and the subcutaneous bradykinin B2 receptor antagonist icatibant (Firazyr) have been available for years for on-demand treatment of HAE attacks; all of these drugs except ecallantide can be self-administered, but treatment delays are common.
In Brief: Label Changes for Menopausal Hormone Therapy Products Free
The FDA has requested the removal of some boxed warnings from the labels of vaginal and systemic menopausal hormone therapy (MHT) products. The warnings were initially added in 2003 based on the results of two placebo-controlled Women's Health Initiative (WHI) trials evaluating the use of systemic hormones for primary prevention of coronary heart disease (CHD) in postmenopausal women 50-79 years old.
In Brief: Removal of Suicidality Warning from GLP-1 Agonists for Weight Management Free
The FDA has requested the removal of the suicidal behavior and ideation warning from the labels of the 3 glucagon-like peptide-1 (GLP-1) receptor agonists approved for chronic weight management: liraglutide (Saxenda) , semaglutide (Wegovy) , and tirzepatide (Zepbound) . The warning was initially included in the labels of these drugs based on an increased risk of suicidal behavior and ideation observed with older weight loss drugs.
Denileukin Diftitox (Lymphir) for Cutaneous T-Cell Lymphoma (online only)
The FDA has approved the interleukin-2 (IL-2) receptor-directed fusion protein denileukin diftitox ( Lymphir – Citius) for treatment of relapsed or refractory stage I-III cutaneous T-cell lymphoma in adults who received at least one prior systemic therapy. Lymphir is a reformulated, purified version of Ontak , which was voluntarily withdrawn from the market in 2014 because of manufacturing issues.
Sevabertinib (Hyrnuo) for NSCLC (online only)
Sevabertinib ( Hyrnuo – Bayer), an oral kinase inhibitor, has received accelerated approval from the FDA for treatment of adults with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) with human epidermal growth factor 2 (HER2) tyrosine kinase domain activating mutations who had received prior systemic therapy. It is the second oral targeted therapy to be approved in the US for this indication; the oral kinase inhibitor zongertinib (Hernexeos) was approved in August 2025.
February 2, 2026 (Issue 1747)
Oral Semaglutide (Wegovy) for Weight Loss
The FDA has approved an oral tablet formulation of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy) for chronic weight management in adults. It is the first oral GLP-1 receptor agonist to be approved in the US for weight management. An injectable formulation of Wegovy was approved for the same indication in 2021.1 The injectable GLP-1 receptor agonist liraglutide ( Saxenda , and generic) and the injectable glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Zepbound) are also FDA-approved for chronic weight management (see Table 1).
Elecsys — A Second Blood Test for Alzheimer's Disease
Elecsys Phospho-Tau (181P) Plasma (Roche), a blood-based diagnostic test, has been cleared by the FDA to aid in the initial assessment of amyloid plaque pathology associated with Alzheimer's disease (AD) in patients ≥55 years old with signs of cognitive decline. It is the second blood test for AD biomarkers to be cleared by the FDA; the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test was cleared in 2025 (see Table 1).
Lumateperone (Caplyta) for Adjunctive Treatment of Depression
The FDA has approved the second-generation antipsychotic drug lumateperone ( Caplyta — Intra-Cellular Therapies) for adjunctive treatment of major depressive disorder (MDD) in adults. Lumateperone was approved earlier for treatment of schizophrenia and bipolar depression.
Risks of Tramadol and Gabapentin Use for Pain
Tramadol ( Ultram , and others) and gabapentin ( Neurontin , and others) are increasingly being prescribed for treatment of chronic pain despite reports of serious adverse events associated with their use. Both drugs are touted as safer and less addictive than strong opioids, but supporting evidence is lacking.
In Brief: New Warning for Injectable Medroxyprogesterone Free
The FDA now requires that product labels for the long-acting injectable progestin contraceptive medroxyprogesterone acetate (MPA; Depo-Provera CI , and generics; Depo-SubQ Provera 104 ) include a warning about the risk of meningioma associated with its use.
January 19, 2026 (Issue 1746)
Sublingual Cyclobenzaprine (Tonmya) for Fibromyalgia
The FDA has approved Tonmya (Tonix), a sublingual tablet formulation of the skeletal muscle relaxant cyclobenzaprine, for treatment of fibromyalgia in adults. Cyclobenzaprine is available in immediate-release tablets and extended-release capsules for short-term treatment of muscle spasms and has been used off-label for treatment of fibromyalgia.
Nalmefene Autoinjector (Zurnai) for Reversal of Opioid Overdose
Zurnai (Purdue), an autoinjector formulation of the opioid antagonist nalmefene, has been approved by the FDA for intramuscular (IM) or subcutaneous (SC) emergency treatment of known or suspected opioid overdose in persons ≥12 years old. Naloxone, another opioid antagonist, has been available in single-use syringes for years. Both nalmefene and naloxone are also available in nasal sprays; some naloxone nasal sprays ( Narcan , and others) are available over the counter.
Donidalorsen (Dawnzera) for Prevention of Hereditary Angioedema Attacks
Donidalorsen ( Dawnzera – Ionis), a subcutaneously injected prekallikrein-directed antisense oligonucleotide, has been approved by the FDA for prevention of hereditary angioedema (HAE) attacks in patients ≥12 years old. It is the first RNA-targeted drug to be approved in the US for this indication.
Imlunestrant (Inluriyo) for Advanced Breast Cancer
The FDA has approved imlunestrant ( Inluriyo – Lilly), an oral estrogen receptor antagonist, for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer in adults who had disease progression following at least one prior line of endocrine therapy. Imlunestrant is the second oral selective estrogen receptor degrader (SERD) to be approved in the US for treatment of breast cancer; elacestrant (Orserdu) was approved in 2023.
In Brief: A New Indication for Uzedy Free
Uzedy , an extended-release, subcutaneous (SC) formulation of the second-generation antipsychotic drug risperidone, was approved by the FDA in 2023 for treatment of schizophrenia in adults. It has now been approved for use as monotherapy or in combination with lithium or valproate for maintenance treatment of bipolar I disorder in adults. Extended-release, intramuscular (IM) formulations of risperidone ( Risperdal Consta and Rykindo ) are also approved for treatment of bipolar I disorder (see Table 1).
In Brief: Andexanet alfa (Andexxa) Withdrawn Free
Andexanet alfa ( Andexxa – AstraZeneca), which received accelerated approval from the FDA in 2018 for urgent reversal of the anticoagulant effect of the direct factor Xa inhibitors apixaban (Eliquis) and rivaroxaban (Xarelto) , has voluntarily been withdrawn from the market. Andexxa was the only drug FDA-approved for this indication in the US.
January 5, 2026 (Issue 1745)
Gepotidacin (Blujepa) — A New Antibiotic for Uncomplicated UTI
The FDA has approved gepotidacin ( Blujepa – GSK), a triazaacenaphthylene bacterial type II topoisomerase inhibitor, for oral treatment of uncomplicated urinary tract infections (uUTI) in female patients ≥12 years old who weigh ≥40 kg. Gepotidacin is the first triazaacenaphthylene antibiotic to be approved in the US.
Remibrutinib (Rhapsido) for Chronic Spontaneous Urticaria
The FDA has approved remibrutinib ( Rhapsido – Novartis), an oral Bruton's tyrosine kinase (BTK) inhibitor, for treatment of chronic spontaneous urticaria in adults who remain symptomatic despite H 1 -antihistamine treatment. Remibrutinib is the first oral drug to be approved in the US for this indication.
Drugs Past Their Expiration Date
Healthcare providers are often asked if drugs can be used past their expiration date. Because of legal restrictions and liability concerns, manufacturers do not sanction such use and usually do not comment on the safety or effectiveness of their products beyond the date on the label. Since our last article on this subject, more data have become available.
In Brief: Alternatives to Bicillin L-A Free
On July 10, 2025 Pfizer issued a voluntary recall of certain lots of long-acting intramuscular (IM) benzathine penicillin G (Bicillin L-A) due to particulates identified during visual inspection. The CDC has issued a "Dear Colleague Letter" to alert healthcare providers about the recall and provide advice on how to manage the potentially limited supply of the drug for treatment of syphilis, which has been increasing in the US.2 Benzathine penicillin G is also used for treatment of group A streptococcal pharyngitis and prophylaxis of rheumatic fever.
Correction Free
In our recent article titled Expanded Indication for PCSK9 Inhibitors (Med Lett Drugs Ther 2025; 67:201), the number needed to treat (NNT) to prevent one composite endpoint of myocardial infarction, ischemic stroke, or death from coronary heart disease in the VESALIUS-CV trial was incorrectly stated as 5 instead of 56. A corrected version of the article appears online:
